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Abstract Amyotrophic lateral sclerosis (ALS) and Hunting-
ton disease (HD) are generally considered to be distinct and
easily differentiated neurologic conditions. However, there are
case reports of the co-occurrence of ALSwith HD.We present
a 57-year-old male with a clinical diagnosis of sporadic ALS
in the context of a family history of HD. This case adds to the
limited literature regarding individuals with a family history of
HD who present with features of ALS. There were several
genetic counseling challenges in counseling this patient in-
cluding the diagnostic consideration of two fatal conditions,
complex risk information, the personal and familial implica-
tions, and the patient’s inability to communicate verbally or
through writing due to disease progression. DNA banking
effectively preserved the right of our patient and his wife not
to learn his HD genetic status during a stressful time of disease
progression while providing the option for family members to
learn this information in the future if desired. We present
lessons learned and considerations for other clinical genetics
professionals who are presented with similar challenging
issues.
Keywords Amyotrophic lateral sclerosis (ALS) . Huntington
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Background
There have been case reports of individuals and families
with features of both amyotrophic lateral sclerosis
(ALS) and Huntington disease (HD), suggesting that
there may be a rare presentation of ALS in individuals
with HD (Rubio et al. 1996, Kanai et al. 2008,
Papageorgiou et al. 2006, Phukan et al. 2010,
Mandrioli et al. 2010, Sadeghian et al. 2011; Tada
et al. 2012; Panse 1942; Gasbarrini 1964; Frank and
Vuia 1973; Myers et al. 1985; Blin et al. 1992; Rubio
et al. 1995; Chettri et al. 2013). These two conditions
are typically considered to have little overlap in
symptomology, though both conditions are fatal, typically
adult-onset neurodegenerative conditions without effective
treatment.
The type of neurodegeneration, associated clinical features,
and genetic basis differ considerably between ALS and HD
(Table 1). ALS causes degeneration of the upper and lower
motor neurons, which leads to progressive muscle weakness,
atrophy, dysarthria, and dysphagia, typically resulting in death
due to respiratory failure within 3–5 years on average (Testa
et al. 2004). Approximately 90 % of ALS cases are sporadic.
The age of onset is highly variable but typically in the
6th or 7th decade for sporadic ALS (Testa et al. 2004)
and the 5th or 6th decade for familial ALS (Juneja
et al. 1997). Ten percent of ALS cases can be attributed
to an autosomal dominant, autosomal recessive, or X-
linked single gene cause and at least 10 genes have
been associated with ALS (Table 1). The cause of ALS in
individuals without a detectable single gene cause is largely
unknown, though some environmental and genetic risk factors
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have been implicated (Kondo and Tsubaki 1981; Armon et al.
1991; Savettieri et al. 1991).
In contrast, HD causes selective degeneration of neurons in
the central nervous system, resulting in cognitive decline, in-
voluntary movements, and psychiatric symptoms (Roos 2010).
The typical age of onset is mid-30s to early 40s (Bates et al.
2002) and death generally occurs within 15–18 years (Harper
and Newcombe 1992). HD is an autosomal dominant disorder
caused by a CAG repeat expansion in the HTT gene (The
Huntington’s Disease Collaborative Research Group 1993).
The prevalence of ALS, 4–8 per 100,000 and HD, 5–7 per
100,000 in the Western European population, give a predicted
co-occurrence rate of 2–6 cases per billion in this population
(Traynor et al. 1999, Walker 2007). However, 11 case reports
of individuals presenting with features of ALS or motor
neuron disease with genetically confirmed HD have been
described (Table 2), along with eight case reports of individ-
uals with concurrent ALS and with a clinical diagnosis of HD
made prior to the availability of HTT genetic testing (Panse
1942; Gasbarrini 1964; Frank and Vuia 1973; Myers et al.
1985; Blin et al. 1992; Rubio et al. 1995). Tada et al. (2012)
hypothesize that a HTT gene mutation predisposes a small
subset of individuals with HTT mutations to develop clinical
and pathological features consistent with ALS (Tada et al.
2012). Among these case reports, most, but not all, individuals
developed concurrent HD symptoms, suggesting that ALS
features could be the primary manifestation of HD in a small
minority of individuals. The possibility that these individuals
developed both HD and ALS by chance alone remains a
consideration.
To add to this literature, we present a 57-year-old Cauca-
sian male with a clinical diagnosis of sporadic ALS in the
context of a maternal family history of HD. We describe the
challenges that arose in this case, including providing genetic
counseling to an individual with a fatal condition who is at risk
for a second fatal condition, and the difficulties with commu-
nication given the patient’s disease progression. We present
lessons learned and considerations for other genetic coun-
selors and clinical geneticists who are presented with similarly
challenging cases.
Table 1 Clinical features and genetics of Amyotrophic lateral sclerosis (ALS) and Huntington disease (HD)
Adult-Onset ALS HD
Prevalence 4–8 per 100,000 (1) 0.1–15 per 100,000 (2)
Average age of onset SALSa - 56 (1); 35–44 (4)
FALSb - 46 (3)
Average disease duration 3–5 years (1) 15–18 years (5)
Clinical features Motor neuron signs: Upper (hyperreflexia and increased
muscle tone) and lower (muscle atrophy, hyporeflexia,
and fasciculations); rarely significant cognitive impairments
Triad of motor (chorea), cognitive (decline to
dementia) and psychiatric symptoms
(depression, personality changes)
Inheritance Sporadic (90–95 %); Autosomal Dominant (5–8 %);
Autosomal Recessive (<1 %); X-linked (<1 %)
Autosomal Dominant (5)
Genetic basis Point mutations in SOD1, TARDPB, FUS, ANG, OPTN, UBQLN2,
other genes; GGGGCC expansion in C9orf72 gene (7–14)
CAG expansion in HTT gene (5)
References:
(1) Testa et al. 2004
(2) Pringsheim et al. 2012
(3) Juneja et al. 1997
(4) Bates et al. 2002
(5) Harper and Newcombe 1992
(6) The Huntington’s Disease Collaborative Research Group 1993
(7) Shaw et al. 1998
(8) Sreedharan et al. 2008
(9) Kwiatkowski et al. 2009
(10) Greenway et al. 2006
(11) Maruyama et al. 2010
(12) Deng et al. 2011
(13) Renton et al. 2011
(14) DeJesus-Hernandez et al. 2011
a SALS Sporadic ALS
b FALS Familial ALS
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Case Report
A 57-year old male patient presented at age 54 with a 6-month
history of painless, progressive left upper extremity muscle
weakness and a 10-month history of diffuse muscle fascicu-
lations. The weakness started in his left hand and progressed
to his proximal arm. He noticed that his muscles became
smaller and that his arm was stiff. Neurologic examination
revealed atrophy of his left upper arm, fasciculations in all
four extremities, and hyperreflexia in the arms. Brain and
cervical MRIs were ordered to rule out any structural cause
for his progressive weakness, but were clinically unremark-
able. An electromyogram showed active denervation and
chronic reinnervation motor nerve injury in both arms. A
repeat electromyogram 6 months later, at age 55, by our
neurologist (JT) showed progression with involvement of his
legs and muscles supporting his thoracic spine, which sup-
ported a diagnosis of probable lab-supported ALS by el
Escorial criteria (Brooks 1994) .
While there was no family history of ALS, our patient’s
family history was significant for HD in his mother, two
siblings, and his maternal grandmother. Each of these relatives
had onset of HD symptoms in the fourth decade and death in
the fifth decade. The family’s medical records were not avail-
able for review, but the patient and his wife did not believe that
any affected family member had genetic testing to confirm the
diagnoses of HD. Our patient had three healthy teenage chil-
dren (Fig. 1). There were no motor, cognitive, or psychiatric
symptoms in our patient concerning for an underlying or
concomitant diagnosis of HD. Given that his symptoms were
not consistent with HD and the many issues that surrounded
his new diagnosis of ALS, his HD risk was not initially
addressed.
The patient was followed in our multidisciplinary ALS
clinic. His weakness progressed over the next 3 years to affect
other muscle groups causing immobility, dysarthria, and dys-
phagia. Approximately 1 year after diagnosis, at age 56, he
began to utilize a power wheelchair for long distances. A few
months later, he experienced speech and swallowing difficul-
ties and started using a speech generation device for commu-
nication. He began to experience dyspnea with minimal exer-
tion and his respiratory function continued to decline. Cogni-
tion, however, remained grossly intact and no formal neuro-
psychiatric testing was initiated.
In regards to his family history of HD, our neurologist (JT)
re-evaluated the patient at age 56 and found no features
Table 2 Case Reports of individuals presenting with features of amyotrophic lateral sclerosis (ALS) or motor neuron disease with genetically confirmed
Huntington disease (HD)
Case Presenting symptoms
(age at presentation)/Gender
Family history Subsequent symptoms
(years of disease duration)
Genetic Test Results
(number of CAG
repeats in HTT gene)
Year, author
1 Cognitive changes (57)/Male ALS (mother);
neuropsychiatric
disorder (maternal uncle)
Chorea, progressive
weakness (23)
HD (45); SOD1
negative
Rubio et al. 1996
2 Chorea (72)/Female Chorea (brother) Muscle atrophy and weakness,
fasciculations (unknown)
HD (40) Papageorgiou
et al. 2006
3 Muscle weakness (41)/Male Chorea (father, siblings) Mild chorea, mild cognitive
disturbance (unknown)
HD (46) Kanai et al. 2008
4 Muscle atrophy, weakness
(56)/Male
HD (paternal first cousin) Chorea, cognitive changes
(unknown)
HD (≥40) Phukan et al. 2010
5 Chorea (63)/Female HD (mother, sister) Dysarthria; dysphagia; muscle
weakness, atrophy, and
fasciculations (6)
HD (43); SOD1
negative
Mandrioli et al. 2010
6 Memory problems (67)/Male Non-contributory Fasciculations, muscle weakness,
chorea (unknown)
HD (40) Sadeghian et al. 2011
7 Chorea, cognitive and
speech changes
(~55)/Female
Chorea (paternal
grandmother)
Muscle atrophy, weakness,
fasciculations, hyperreflexia (~6)
HD (46) Tada et al. 2012
8 Chorea, cognitive changes
(~35)/Female
HD (father, paternal
grandfather, sister,
other relatives)
Rigidity followed by hypotonia,
autopsy consistent with ALS
(20–25)
HD (47) Tada et al. 2012
9 Chorea (~55)/Female HD (mother, maternal
grandmother, siblings)
Muscle weakness (~12) HD (42) Tada et al. 2012
10 Dysarthria (56)/Female HD (father) Muscle weakness (2) HD (39) Tada et al. 2012
11 Irritability (48)/Male HD (mother, brother) Muscle atrophy, fasciculations,
dysarthria, dysphagia,
hyperreflexia (9)
HD (>39) Chettri et al. 2013
≥40 CAG repeats in HTT gene is consistent with Huntington disease. 39 CAG repeats is reduced penetrance allele
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consistent with HD. He had normal eye movements with
normal saccades and no dystonia, tremor, choreaform
movements, or known cognitive or psychiatric distur-
bances. However, it was noted that his significant mus-
cle weakness likely would have precluded the exhibition
of some of the characteristic symptoms of HD. The
finding of normal eye movements was of particular
importance since HD typically causes marked abnormal-
ities of ocular motility, while ocular motility remains
grossly normal until the latest stages of ALS (Mizutani
et al. 1990, Roos 2010).
At this time, our genetic counselor (AS) joined the multi-
disciplinary ALS clinic and became involved in this case. The
patient was reminded of his 50% a priori risk for HD given his
family history. Based on this risk, as well as case reports
indicating that a rare subset of individuals with HD may
present with features of ALS (Table 2), the clinic’s genetic
counselor (AS) presented the option to have genetic testing for
HD and discussed the personal and familial implications of
HDwith the patient and his wife. The patient’s wife facilitated
communication, as the patient’s dysarthria had made his ver-
bal communication unintelligible and hand immobility ren-
dered him unable to write. He was also no longer able to use
his speech generation device because progressive limitations
in his head range-of-motion made the device’s head-
controlled mouse ineffectual. Direct communication with
our patient was limited to yes/no questions to which he
responded with eye and head movements.
The patient and his wife were overwhelmed by this HD
risk, as it differed from their former understanding of his risk.
The recent loss of the patient’s ability to speak and swallow
also added significant stress to the situation. The couple
requested that the genetic counselor (AS) return for further
discussion about HD genetic testing at the time of an upcom-
ing hospitalization for a feeding tube placement. During this
discussion, the patient’s wife revealed that the patient had
genetic counseling as a young man and that the couple had
planned to use a sperm donor to avoid the possibility of
passing HD to their children. However, they felt that he was
“in the clear”when he passed the familial age of onset and the
couple elected not to pursue testing or to utilize a sperm donor.
They went on to have three healthy children who they pre-
sumed were not at risk to develop HD.
During these conversations, the patient’s wife revealed a
culture of secrecy in the family, including deaths fromHD that
had not been revealed as such and relatives’ fear that revealing
this information would affect family members’ marriageabil-
ity. Though the couple’s own children were aware of HD in
the family, the patient’s wife did not wish her children to be
informed of the recent discussions regarding his HD risk; she
felt it would be an additional psychological burden on the
children to have to consider the possibility of their own future
Fig. 1 Pedigree
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with HDwhile coping with their father’s rapid deterioration in
health. Therefore, she requested that the genetic counselor not
discuss the topic if the children were to enter the room.
Though our patient retained legal guardianship over med-
ical decision-making, it became clear through yes/no
questioning that our patient gave the decision-making right
and responsibility for his own genetic testing to his wife. She
revealed that she felt internal pressure to make the responsible
decision in regards to his testing for their children’s sake and
that she did not feel that she was ready to deal with potentially
positive HD results. Coping with her husband’s terminal
illness compounded the difficulty of facing the possibility that
her children may be at risk for an equally devastating condi-
tion. Nevertheless, some hope was provided when discussing
the children’s risk of HD given their young ages and the
potential for medical advances. She expressed hope that more
medical treatments may be available to her children if they
were to develop HD than were available to her husband and
his family members.
Further conversations made it evident that they were not
ready to make a decision about HD genetic testing. The option
of DNA banking was presented as an alternative. DNA bank-
ing would preserve and ensure a sample from our patient was
available for future genetic testing should the patient or his
family members decide that they would like to know whether
or not he had a gene mutation for HD, but would remove the
pressure to make a decision or proceed with genetic testing
during a stressful time. A follow up phone call by the genetic
counselor (AS) to the patient’s wife confirmed their decision
to pursue DNA banking. Blood was drawn by a home
healthcare professional and sent to a laboratory offering clin-
ical DNA banking.
Home hospice care was initiated for our patient within
weeks of banking his DNA. He passed away 6 months later
at the age of 57 in his home due to respiratory failure. A brain
and cervical spine autopsy was performed on our patient as
part of an ongoing research protocol. The brain autopsy re-
vealed atrophy of the ventral nerve roots and astrogliosis of
the cortical spinal tracts, consistent with a diagnosis of ALS.
The brain weight was within normal limits and there was no
observed atrophy of the striatum, as would be expected in a
patient with HD. The patient’s wife was informed of the
autopsy results.
Discussion
This case adds to the limited number of cases which have been
reported of individuals with ALS in the context of a family
history of HD. In addition, this case presented several genetic
counseling challenges given the diagnostic consideration of
two fatal conditions, complex risk information, the personal
and familial implications, and the patient’s inability to
communicate verbally or through writing due to disease pro-
gression. This case offers several learning points for the ge-
netic counseling community at large, and especially for those
genetic counselors and clinical geneticists working with pa-
tients with fatal, neurodegenerative diseases.
Risk Assessment
Though our patient’s a priori risk for HD was 50 % given his
family history of HD, his risk at age 57 was more difficult to
assess. Bayesian analysis based on age-related HD penetrance
estimates could be utilized to calculate an estimated current
risk for HD of approximately 22 % (Harper and Newcombe
1992). The rare possibility that our patient’s ALS symptoms
could have resulted from an underlying HTT mutation com-
plicate these calculations. Our patient’s age of ALS symptom
onset is similar to these case reports and like cases 3, 4, and 9,
our patient presented with symptoms of motor neuron degen-
eration in the context of a 50 % a priori risk to develop HD.
Like case 9, our patient had not developed any known features
of HD in the years since his initial ALS symptom onset
(Table 2).
Determining the appropriate risk information to convey to
the patient and his wife given this complex risk assessment
was also a challenge in this case. Genetic counseling had to
effectively convey each of the following possibilities: 1. that
our patient had sporadic ALS coincidentally in the context of a
family history of HD and he did not inherit the HD allele, 2.
that he had sporadic ALS coincidentally in the context of a
family history of HD and he had inherited an HD allele and
was not yet symptomatic, or 3. that his ALS symptoms were
actually an unusual phenotype of HD. For the latter two
possibilities, each of his children would have a 50 % risk for
HD. The likelihood of each of these possibilities was un-
known, given the limited understanding of how often HTT
expansions cause a clinical picture of motor neuron disease.
Predictive or Diagnostic HD Testing?
Another challenge that arose was whether our patient’s HD
genetic testing should be treated as predictive because he had
no clear findings of HD or diagnostic given the aforemen-
tioned case reports (Table 2). Our patient’s physical limita-
tions and the time, travel, and effort involved in the additional
appointments stipulated in the HD predictive genetic testing
guidelines (International Huntington Association 1994,
MacLeod et al. 2013) would have been a barrier to proceeding
with predictive genetic testing. In addition, the utility of
following the predictive testing protocol for our patient, who
was already suffering from a fatal, neurodegenerative condi-
tion with a shortened lifespan, was likely limited compared to
a truly presymptomatic patient.
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This case made us consider the distinctions between diag-
nostic and predictive testing and when it is appropriate to
modify the existing predictive HD testing protocol. For our
patient, modifications would have been necessary given his
physical limitations and fatal condition. In particular, modifi-
cations to the specified number of visits and timing between
visits would have been required. Flexibility in carrying out
protocols for predictive testing for late-onset neurodegenera-
tive diseases was supported by a recent qualitative study of
individuals undergoing predictive testing (Guimaraes et al.
2013), as well as in guidelines published in 2013 for predictive
genetic testing for adult-onset monogenic conditions (Skirton
et al. 2013).
Family Culture and “in the Clear” Thinking
Beyond the difficulty with risk assessment, genetic counseling
for this patient and his wife was further complicated by the
broader family dynamics and the nuclear family’s risk beliefs.
The family culture of secrecy surrounding HD was a possible
inhibiting factor in identifying at-risk and affected relatives,
decision-making about testing, and potentially disclosing in-
formation. In addition, our patient’s wife’s decision not to
discuss the conversations regarding their father’s HD risk
was consistent with the culture of secrecy surrounding this
diagnosis. This decision is consistent with several studies
which have reported that a family history of HD is not always
disclosed within a family (Forrest et al. 2003; Forrest Keenan
et al. 2009; Holt 2006; Klitzman et al. 2007; Nagaraja et al.
2006; Quaid et al. 2010). Our case report highlights that a
culture of secrecy may be created and maintained with altru-
istic, if not paternalistic, intentions to protect family members.
The patient’s wife cited protecting her children from unnec-
essary psychological stress as the reason for not disclosing his
HD risk immediately.
Additionally, the patient and his wife felt that he was “in the
clear” for HD since he was older than the familial age of onset.
This historically held belief appeared to affect their ability to
process and cope with new conflicting information regarding
his HD risk. It appeared that the dissonance created by the
possibility that he had inherited HD was intensified by their
“in the clear” thinking and the predictive testing and repro-
ductive decisions that they had made based on this assump-
tion. As our case illustrates, it is important to assess risk beliefs
and family dynamics in communication of medical
information.
Counseling Communication-Impaired Patients
Communication was a significant genetic counseling chal-
lenge in this case because of our patient’s inability to effec-
tively communicate verbally or through writing. Assessment
of our patient’s nonverbal communication was also limited
given his disease progression, which significantly limited his
physical movements. Genetic counseling typically relies on
verbal communication for interviewing and psychosocial as-
sessment, as well as nonverbal cues (Uhlmann et al. 2009).
Therefore, alternative approaches had to be used in order to
establish a working relationship with the patient and under-
stand his needs and desires. Our approach was to limit the
information conveyed to what was most necessary to commu-
nicate and to utilize yes/no questioning to facilitate our pa-
tient’s involvement. Additional counseling time was also pro-
vided to accommodate the patient’s limitations. More typical
genetic counseling communication methods were employed
with the patient’s wife, who served as a representative for her
husband.
No genetic counseling guidelines currently exist for pro-
viding counseling to individuals who require speech genera-
tion devices or other forms of communication assistance.
However, approximately 95 % of individuals with ALS will
lose their ability to communicate verbally (Ball et al. 2004)
and lack or loss of intelligible speech is also present in other
genetic conditions. Therefore, genetic counselors, especially
those working in neurogenetics, need to be prepared to coun-
sel nonverbal or communication-impaired patients. Based on
our experience with this patient and others, use of yes/no
questioning and limiting presented information can facilitate
participation of nonverbal patients in genetic counseling.
Facilitating Decision-Making for Patients with Life-Limiting
Conditions
Facilitating decision-making in an individual with a life-
limiting condition brought a new set of challenges and com-
plexities to this case as well. The timing of counseling during a
period of medical crisis and after severe progression of the
condition also affected the family’s level of stress and anxiety
surrounding the decision-making process.
Doing it for the Children
For our patient and his wife, the strongest motivating factor in
decision-making about HD genetic testing was their children,
as this information did not hold promise of changing our
patient’s prognosis or medical treatment. Our patient’s wife’s
decision-making was motivated by the responsibility to do the
right thing for her children’s sake. However, she had an
internal conflict as to what the “right thing” for her children
was. The feeling of obligation to children that our patient’s
wife expressed is commonly cited by individuals at-risk for
HD as a factor affecting their decision to undergo predictive
testing (Bloch et al. 1989; Craufurd et al. 1989; Dufrasne et al.
2011; Evers-Kiebooms et al. 1989; Evers-Kiebooms et al.
2002; Quaid and Morris 1993; Smith et al. 2013). Providing
children with relevant information for their reproductive
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decision-making can also influence parental decisions to test
or not test (Smith et al. 2013).
The conflict that our patient’s wife felt about whether this
obligation to children promoted or inhibited a decision to test
has also been acknowledged in the HD literature. For exam-
ple, Craufurd et al. (1989) found that an important motivating
factor for individuals undergoing predictive HD testing was to
clarify the risk for their existing children, while Quaid and
Morris (1993) found the biggest factor in at-risk individuals’
choice not to undergo predictive testing was “if my risk goes
up so does that of my children.” Therefore, a feeling of
obligation to children can either promote or prevent someone
from undergoing genetic testing. Our patient’s wife showed
that decision-making can be especially distressing when con-
flicting internal notions exist as to whether or not genetic
testing would benefit or harm the children.
Deferring Decision Making to Others
As noted above, our patient deferred decision-making regard-
ing HD genetic testing to his wife because the results were
most relevant to their children. Implicit in his decision to
transfer decision-making authority to his wife was the knowl-
edge that she would soon become the sole parent to their
children. The use of a family member as the decision-maker
regarding genetic testing, as we observed with our patient’s
wife, may provide some genetic counselors with an internal
uneasiness given the profession’s commitment to preserving
patient autonomy and preventing undue coercion from family
members (National Society of Genetic Counselors 2013).
However, genetic counselors need to recognize and take into
account how the patient’s diagnosis and prognosis affect
decision-making and explore the patient’s wishes to defer
genetic testing decisions to family members, who likely will
be more affected by results than the patient him/herself. In
some cases, allowing the patient to defer decision-making to
another family member should be viewed as respecting, in-
stead of violating, the autonomy of a patient with a life-
limiting condition.
DNA Banking
DNA banking allows for long-term storage of DNA and is
particularly useful for patients with life-limiting conditions
(Uhlmann et al. 2009; National Society of Genetic
Counselors 2013). Determining our patient’s carrier status
for HD would have clarified his children’s risk for developing
this condition. However, the patient and his wife were not
ready to learn this information. Their decision was under-
standable given the limited life span of our patient and the
expressed desire to protect the family from more immediate
painful news. DNA banking was a beneficial option to con-
sider because it preserved the right of our patient and his
family not to know his HD genetic status, while providing
the option for this information to be learned in the future, if
desired.
Summary
This case adds to the literature regarding individuals with a
family history of HD who present with features of ALS.
Genetic counseling to patients for whom more than one con-
dition is being considered will become more common, as the
availability of genomic testing increases and our understand-
ing of the phenotypic spectrum of single gene disorders ex-
pands. In addition, this case presented challenges and potential
solutions for facilitating effective communication with non-
verbal, cognitively intact patients, as well as with patients with
fatal conditions. Lastly, this case reinforced the utility of DNA
banking in the practice of genetic counseling.
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